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Reviews
Cell and Gene Therapy for Genetic Diseases: Inherited
Disorders Affecting the Lung and Those Mimicking
Sudden Infant Death Syndrome
Allison M. Keeler and Terence R. Flotte
Abstract
Some of the first human gene therapy trials targeted diseases of the lung and provided important information that
will continue to help shape future trials. Here we describe both cell and gene therapies for lung diseases such as cystic
fibrosis and alpha-1 antitrypsin disorder as well as fatty acid oxidation disorders that mimic sudden infant death
syndrome (SIDS). Human clinical gene therapy trials for cystic fibrosis and alpha-1 antitrypsin have been performed
using a variety of vectors including adenovirus, adeno-associated virus, and nonviral vectors. No human clinical
gene therapy trials have been performed for disorders of fatty acid oxidation; however, important proof-of-principle
studies have been completed for multiple fatty acid oxidation disorders. Important achievements have been made
and have yet to come for cell and gene therapies for disorders of the lung and those mimicking SIDS.
Introduction
Genetic disorders commonly treated by pediatric andadult pulmonary physicians have been targets of great
interest in the field of gene therapy, and more recently in the
field of stem cell therapy as well. Most notably in the early
history of human gene therapy trials, a broad initiative led by
the Cystic Fibrosis (CF) Foundation drove the efforts to bring
new gene therapy vectors into clinical use. Because of this, the
first human use of both recombinant adenovirus (rAd) and
recombinant adeno-associated virus (rAAV) vectors occurred
in CF patients in 1993 and 1995, respectively (Crystal et al.,
1994, 1995; Flotte et al., 1996, 2003). Many lessons were learned
about vector safety and duration of effect from those early
trials, even though neither has led to the development of clin-
ically effective therapies at this point. Gene and cell therapy
approaches for CF remain an active topic of research in many
laboratories as more varied approaches including integrating
lentivirus vectors and novel approaches to airway and lung
regeneration.Most notably, artificial tracheas repopulatedwith
human stem cells have been used clinically in Scandinavia to
treat patientswith surgically irreparable damage to the trachea,
providing a potential proof of concept for more extensive cell-
based repopulation of the respiratory tract that could eventu-
ally be applied to airway diseases like CF (Anonymous, 2011).
Meanwhile, the attention to treatment for genetic disor-
ders within the practice of pulmonologists has broadened to
include genetic emphysema due to alpha-1 antitrypsin
(AAT) deficiency and genetic disorders that contributed to
over 5% of cases of sudden infant death syndrome (SIDS)
(Boles et al., 1998). Clinical protocols with rAAV-based vec-
tors for AAT deficiency have progressed through phase 2
and remain currently active. This disorder mimics other de-
ficiencies of secreted serum proteins such as hemophilias.
Meanwhile, the advent of newborn screening for metabolic
diseases has revealed populations of patients with disorders
of fatty acid oxidation (FAO), the most frequent of which is
medium chain acyl-CoA dehydrogenase (MCAD) deficiency.
Without this screening, affected individuals would likely
succumb to SIDS. Interventions to treat the genetic basis of
FAO disorders seem more likely to affect the outcome in
such infants, as compared with the previous approach to
familial cases of SIDS, which was home apnea monitoring.
The rAAV-based proof-of-principle studies for FAO disor-
ders have generally been aimed at correction of cardiac and
skeletal muscle (which metabolizes the largest proportion of
fatty acids), the liver (which can use FAO to help generate
ketones as a protection against fasting hypoglycemia), or the
entire body (which could assist with both the accumulation
of toxic metabolites and the lack of ATP generation caused
by the disorder).
Taken together, the experiences garnered from attempts to
develop gene and cell therapy for inherited diseases affecting
the lung and ventilator control have both contributed to and
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benefited from technological advances in the field more
generally. Genetic diseases in this category have been
somewhat difficult as targets in the past because of the
dearth of truly faithful animal models of CF and AAT defi-
ciency and, in the case of CF, because of the truly recalcitrant
nature of the target cell itself, the airway epithelial cell.
Airway epithelial cells are actively replicating, making gene
therapy with nonintegrating systems more challenging, and
have evolved a number of barriers on the luminal surface
that may limit the efficiency of entry of most vectors. The
complex tissue architecture of the organ also presents chal-
lenges to cell-based therapies not encountered in the bone
marrow, for instance. That said, these disorders represent
several of the most common single gene defects in North
Americans and Northern Europeans and so will undoubt-
edly continue to garner much effort and attention.
Cystic Fibrosis
Disease
CF is the most common life-threatening single gene dis-
order in North America, with an incidence of 1 in 3300 live
births and over 30,000 CF patients known to be living on the
continent (FitzSimmons 1993). It is due to defects in the CF
transmembrane conductance regulator (CFTR) gene, a
member of the ATP-binding cassette superfamily of trans-
membrane transporters. CFTR is normally present on the
apical surface of airway epithelial cells and submucosal
gland cells where it performs a number of vital functions,
including acting as a protein kinase A–dependent chloride
channel (Welsh et al., 1992; Hanrahan et al., 1998; Seibert
et al., 1999; Ostedgaard et al., 2001) and a regulator of other
chloride channels and the epithelial sodium channel (Briel
et al., 1998; Ko¨nig et al., 2001; Wagner et al., 2001).
In the absence of CFTR function in the conducting airways
of the respiratory tract, chloride efflux is decreased, sodium
absorption is markedly increased (Olivier et al., 2002), and
the net flux of water into the airway surface lining fluid is
markedly diminished (Boucher, 2003). There may also be
secondary effects on the biochemical composition of mucous
glycoproteins and the function of antimicrobial substances at
the airway surface. The overall effect is that CF patients have
obstruction of small airways, inflammation, and chronic in-
fection with specific bacteria, such as Pseudomonas aeruginosa,
Staphylococcus aureus, Burkholderia cepacia, and several others.
CFTR normally functions in a number of other secretory
epithelia, including the pancreatic ducts, the sweat gland
ducts, and the vas deferens. CFTR deficiency at these sites
results in exocrine pancreatic insufficiency, elevated sweat
chloride concentrations, and male infertility in the vast ma-
jority of patients. Other complications occurring more fre-
quently in older CF patients include CF-related diabetes and
osteoporosis. A subset of CF patients will develop severe
intestinal obstruction prenatally or immediately after birth
(known as meconium ileus), while others may develop sig-
nificant cholestatic liver disease, presumably due to absence
of vital CFTR functions on enterocytes and biliary duct lining
cells.
Treatment for CF has continuously evolved over the past
50 years, resulting in improvements in life span from an
average of less than 5 years to the current median life ex-
pectancy of over 40 years in the United States (Cystic Fibrosis
Foundation, 2010). Treatment consists of nutritional support
through oral administration of enteric coated pancreatic en-
zymes to prevent malabsorption, supplementation of fat
soluble vitamins, and caloric augmentation to compensate
for increase metabolic rates in these patients. Therapy for CF
lung disease includes aggressive airway clearance (using a
variety of physical methods and mucolytic drugs, such as
rhDNase and hypertonic saline) (Lieberman, 1968; Jones and
Wallis, 2010) and aggressive antibiotic therapy (including
intravenous, inhaled, and oral therapies). More recently,
specific small molecule therapies that correct or activate
mutant CFTR chloride channels have been developed, in-
cluding Kalydeco, the recently approved drug from Vertex
Pharmaceuticals, which works specifically on the G551D al-
lele to correct trafficking of mutant CFTR to the cell surface
(Accurso et al., 2010; Ramsey et al., 2011). Trials are currently
ongoing in which Kalydeco will be combined with a new
CFTR activator (VS809) to treat patients with the most
common mutation, deltaF508. The concept is that Kalydeco
will correct trafficking that VX880 allows for increased acti-
vation of the mutant CFTR. While such small molecule
therapies represent great progress for the field, there remains
significant interest in the possibility that the primary defect
may eventually be corrected definitively at the genetic level.
These efforts, past and present, will be presented in follow-
ing sections.
rAd-gene therapy
First generation rAd vectors expressing CFTR were de-
leted for the E1a, E1b, and E3 genes. These vectors demon-
strated very robust levels of expression of either CFTR or of
reporter genes in cell culture and in animal models. A
number of human phase 1 clinical trials were begun in 1993,
the first commencing at the National Institutes of Health
(Crystal et al., 1994). Several key findings emerged from these
trials. First, it became clear that there was a dose-related
innate immune response to the vector (Fig. 1) as well as an
adaptive immune response. These limited both the
FIG. 1. Serum anti-adenovirus (Ad) antibodies elicited by
administration of AdCFTR to the respiratory tract. (Origin-
ally published in Crystal et al. [1994] and reprinted by per-
mission [license number 2891420070068].) Serum was
evaluated for anti-Ad antibodies before and after adminis-
tration of AdCFTR. Anti-AdCFTR antibodies detected by
enzyme-linked immunosorbent assay (ELISA). The ordinate
is presented as the inverse of the maximum dilution of serum
yielding a value higher than the highest value observed
during the baseline and/or vehicle control period (pre-Rx).
CELL AND GENE THERAPY FOR INHERITED LUNG DISORDERS 549
maximum tolerated dose and the duration of transgene ex-
pression. The second, somewhat surprising finding was that
the efficiency of gene transfer in the airways was much lower
than predicted. Ultimately, it became clear that the required
receptors for rAd transduction (CAR and alphav, beta5 in-
tegrins) were more abundant on the basolateral membranes
of airway epithelial cells than on the apical surface.
These limitations further drove the development of rAd
vector technology. Second-generation rAd vectors were de-
veloped with additional mutations in early genes, most no-
tably the incorporation of a temperature-sensitive mutation
in the E2a gene (Yang et al., 1994). Finally, fully deleted rAd
vectors were developed. These vectors, alternatively known
as gutted, gutless, high-capacity, or helper-dependent rAd
(HD-rAd), were constructed such that only the noncoding
sequencing of the Ad inverted terminal repeats (ITRs) were
present within the vector (Palmer and Ng, 2005).
With each advancing generation of vector the duration of
vector gene expression was enhanced in animal models and
the adaptive immune response profiles were reduced.
However, the presence of both an innate immune response to
the input capsid components and the eliciting of neutralizing
antibodies to the input capsid represented inherent limita-
tions. Nonetheless, HD-rAd vectors are still in experimental
use in animal models for a variety of diseases. Unfortunately,
the fact that the airway epithelium is actively replicating still
limits the duration of gene expression in that tissue, and the
presence of neutralizing antibodies limits the ability to pre-
serve efficiency after repeated dosing.
rAAV gene therapy
As with rAd vectors, the first in vivo animal and clinical
use of rAAV gene therapy vectors were directed at CF (Flotte
et al., 1993a, 1996). Unlike rAd vectors, rAAV vectors are
nearly always fully deleted of vector coding sequences be-
cause of the very limited packaging capacity (< 5 kb) of
the virion, which necessitates the creation of space within the
vector genome for the transgene, its promoter, and the
polyadenylation signal. Even with deletion of both the viral
genes (rep and cap), the packaging of CFTR into rAAV has
represented a significant challenge, since the coding se-
quence of CFTR alone measures 4.4 kb in length. Therefore,
the earliest efforts centered around developing vectors uti-
lizing very small promoter sequences, such as the cryptic
promoter activity of the AAV2 ITR (Flotte et al., 1993b), or on
developing truncated CFTR transgenes (Carroll et al., 1995;
Sirninger et al., 2004).
Based on in vivo data in rabbits and nonhuman primates,
the first clinical trials of rAAV2-CFTR were launched in
November 1995. The original trial consisted of combined
nasal and endobronchial administration. This trial was ex-
tended several times and finally covered more than a 6-log-
fold dose range, establishing safety and biological activity
over that entire range. Additional studies with the original
ITR promoter–driven rAAV2-CFTR vector were performed
in the sinuses and by aerosol delivery to both lungs. The
latter studies showed gene transfer to the lower airways that
persisted for 60 days, consistent with the turnover of the
airway epithelium (Moss et al., 2004). The development of
neutralizing antibodies was correlated with the inability to
achieve gene transfer again after subsequent doses.
It was originally in the context of lung delivery of these
vectors that the episomal nature of rAAV persistence was
discovered (Flotte et al., 1994; Afione et al., 1996). Ultimately,
this led to the prediction that rAAV would be most effective
at long-term gene expression in cells and tissues that were
terminally differentiated or quiescent. This has subsequently
proven to be true, as the most effective uses of rAAV vectors
have been in the retina, central nervous system, and unin-
jured liver or muscle. In addition to the barrier presented by
the turnover of airway epithelium, it was discovered that
AAV2 uses receptors that are low in abundance on the apical
surface of airway epithelium (Teramoto et al., 1998; Sum-
merford et al., 1999).
Newer generations of rAAV vectors have been developed
using different serotypes (rAAV5, rAAV1, rAAV-rh10) and
stronger promoters, such as the cytomegalovirus (CMV)
enhancer/beta actin promoter/beta globin hybrid intron
(CBA or CAG) cassette. Due to the constrained packaging
capacity, these vectors require either a truncated CFTR
minigene (Carroll et al., 1995; Sirninger et al., 2004), or a dual
vector approach that relies on dimerization between two
vector constructs containing each half of the gene with a split
intron (Song et al., 2009).
Lentiviral and retroviral gene therapy
Based on the potential advantage for vector integration,
many studies have been performed using a variety of gamma
retrovirus and lentivirus vectors to target the airway epi-
thelium. Generally, these vectors have been pseudotyped
with envelopes that are suitable for targeting receptors
present on airway epithelial cells. These have included the
vesicular stomatitis virus-G glycoprotein, the Gibbon ape
leukemia virus envelope, and an envelope targeting the fo-
late receptor (Bayle et al., 1993; Copreni et al., 2010). In gen-
eral, the longevity and safety of such systems have been
quite good. However, the gamma retrovirus vectors have
generally required some form of stimulus to promote cell
division within the airway epithelium in order to facilitate
transduction.
Nonviral gene therapy
Much of the early work in CF gene therapy focused on the
use of cationic liposomes for CFTR delivery. The most
promising of these, Genzyme Lipid-67 (GL-67) was used in a
trial several years ago, and the combination of lipid and
DNA was found to elicit some innate immune responses that
cause flu-like syndromes in some of the patients (Alton et al.,
1999; Ruiz et al., 2001; Konstan et al., 2004). Further refine-
ments of the plasmid have been carefully studied, and GL-67
is being studied again in a program undertaken by the UK
CF Gene Therapy Consortium. DNA compacted with poly-l-
lysine has also been brought forward into clinical trials and
has shown some reproducible but transient gene expression
(Ziady et al., 2003).
Cell-based therapy
Cell-based therapies for the airways have been under
study for a number of years. The concept of using stem cells,
derived from hematopoietic stem cells or human embryonic
stem cells, has been studied by a number of groups, and the
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engraftment rate appears to be quite low. The use of repro-
grammed cells (induced pluripotent stem cells) has also been
contemplated.
More recently, tracheal grafts composed of a synthetic
matrix populated with cells derived from stem cells have
been used in Scandinavia for tracheal transplants following
cancer or trauma (personal communication). This technology
has not yet undergone clinical evaluation in the United
States. It remains to be seen whether such technology could
have a use in genetic disorders like CF. A similar concept has
been used to produce a repopulated lung in a rodent model
(Weiss et al., 2011). In this case the endogenous matrix of a
lung is denuded by serial freeze–thaw cycles and then re-
populated with pluripotent cells. While early results seem
quite remarkable, the clinical utility of this technology re-
mains to be seen.
AAT Deficiency
Disease
AAT is a highly abundant circulating 52 kD serum pro-
teinase inhibitor (serpin), which is normal produced primarily
in hepatocytes (to a lesser extent in macrophages and mono-
cytes) and circulates at levels exceeding 11lM (570lg/ml) to
protect the lung extracellular matrix from the effects of neu-
trophil elastase and other neutrophil products. AAT defi-
ciency typically results in an adult onset lung disease,
characterized by panacinar emphysema and airway inflam-
mation. A small subset of patients (< 10%) will develop
symptomatic liver disease, which appears to be due to the
effects of the common mutant protein, a Glu342Lys substitu-
tion called PiZ. PiZ-mutant AAT (Z-AAT) is hampered by the
loss of a salt bridge between two beta-sheet structures, which
inhibits its anti-elastase specific activity, impairs folding, and
allows the reactive loop of one Z-AAT molecule to insert itself
between two beta strands of an adjacent Z-AAT, enabling so-
called ‘‘loop-sheet’’ polymerization (Elliott et al., 1998). AAT
deficiency is very homogenous genetically, with over 90% of
mutant alleles being PiZ. Thus, it is unclear why some PiZ
homozygotes develop liver disease in response to the presence
of Z-AAT, while others do not. Nonetheless, it remains rea-
sonably clear that lung disease is treatable by replacement of
wild-type AAT (M-AAT) to levels above 11lM (570lg/ml),
while the treatment of liver disease, would likely require
down-regulation of Z-AAT within hepatocytes.
Cationic lipid-based gene therapy
Cationic liposomes have been used to augment AAT levels
in animal models via a number of routes. In fact, the nasal
instillation of cationic lipids in a phase 1 human trial was
described some years ago (Brigham et al., 2000). The lack of
persistence of gene transfer with this method is a major
limitation, as is the very high level of gene augmentation
required to achieve therapeutic effects.
rAAV-gene therapy
Significant effort has been put toward the development of
rAAV-AAT gene therapy, including both augmentation for
therapy of the lung disease (which has gone through phase 2
clinical trials) andallele-specificZ-AATliver-directedknockdown
(which has only been studied in animal models at this point).
The study of gene augmentation for M-AAT is greatly
aided by the fact that C57Bl6 (B6) mice naturally have tol-
erance for hAAT (Song et al., 1998, 2001). Thus rAAV-hAAT
vectors were studied directly in B6 mice. Studies of intra-
muscular (IM), portal vein, airway delivery, and intrapleural
delivery have all led to the production of stable, high-level
hAAT expression (Conlon et al., 2005; Virella-Lowell et al.,
2005). Additional preclinical studies in nonhuman primates
have assisted in the clinical translation of IM AAT delivery.
An initial phase 1 trial was performed using a serotype 2
rAAV-AAT vector, but the levels were too low to justify
further pursuit of this avenue (Brantly et al., 2006). Subse-
quently, both phase 1 and phase 2 trials of rAAV1-AAT IM
delivery have been performed (Brantly et al., 2009; Flotte
et al., 2011). Dose-related expression, persisting for up to 1
year has been seen, even in the face of T-cell responses to the
AAV capsid and in the absence of immune suppression. The
levels in the phase 2 trial (at doses of up to 6· 1012 viral
genome [vg]/kg or 5· 1014 vg per patient) were approxi-
mately 3% of the therapeutic target (Fig. 2). Future trials will
seek to further increase the dose by moving to limb perfusion
methods, which will allow for a greater volume of vector to
be delivered over a greater mass of muscle. This is particu-
larly necessary since the top dose in the most recent trial
entailed 100 injections during a single procedure.
Other gene therapy
AAT augmentation has also been accomplished in animal
models using retrovirus vectors, SV40 vectors, and nonviral
vectors (Zern et al., 1999). First and second generation rAd
vectors and HD-Ad vectors have also been used to achieve
high levels of AAT augmentation in animal models but have
FIG. 2. Serum M-specific alpha1-antitrypsin (AAT) con-
centration after injection of rAAV1-CB-hAAT produced by
plasmid transfection (TFX) or the herpes simplex virus (HSV)
method. (Originally published in Flotte et al. [2011] and
reprinted with permission by Flotte et al.) Values shown
represent means – SD. The dose of vector administered to
subjects is indicated in the figure legend. Values for the TFX
group are from a previous study (Brantly et al., 2009). Values
for the 6· 1011 vg/kg HSV group do not include results for
subject 303 who had an AAT phenotype of SZ; the mono-
clonal antibody used to determine serum M-specific AAT
concentrations had little cross-reactivity with Z-type AAT
but cross-reacted strongly with S-type AAT, causing results
for this assay in this subject to be spuriously high. vg, viral
genome.
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faced the same limitations described above. The clinical
utility of such approaches has yet to be tested.
Cell-based therapy
Cell-based therapy of AAT lung and liver disease might be
accomplished if one could identify a population of cells,
which could be genetically corrected and then used to re-
populate the liver. This has been modeled in mice using oval
cells (an endogenous liver cell progenitor found in mice).
Using oval cells for ex vivo rAAV-AAT gene therapy, re-
population was demonstrated by Song et al. (2004), resulting
in stable AAT expression over several months. The clinical
practicality of such approaches remains in question, partic-
ularly since the human equivalent of oval cells has yet to be
identified. However, the availability of reprogramming
technology has restored some interest in this approach.
Disorders of FAO
Background of FAO
FAO is a cyclic process in which fatty acids are broken
down to produce energy. FAO is also important in removing
toxic accumulations of certain fatty acids, such as short
branched-chain fatty acid created by degradation of branched-
chain amino acids. Under normal fed conditions, many or-
gans prefer to get most of their energy from glycolysis, but
under certain conditions, such as fasting, exercise, or meta-
bolic stress, FAO is an important source of energy. However,
the heart’s preferred energy source, from which it derives
70%–95% of its energy, is FAO (Bing et al., 1954; Neely and
Morgan, 1974). In utero a fetus receives a constant supply of
glucose from the placenta, but after birth an infant receives
60% of it calories from fat in breast milk, so highly oxidative
tissues must rely on FAO for energy (Goetzman 2011).
During periods of fasting the liver uses FAO to produce
acetyl-CoA to produce ketones. The ketones can then be used
for energy in the brain, where glucose is the preferred energy
source. Skeletal muscle also uses FAO as an energy source
when energy is in high demand during exercise.
FAO can take place either in the mitochondria or in the
peroxisomes, but generally peroxisomes only handle un-
usual fatty acid species and those with chain lengths greater
than 20 carbons, which are shortened, and then oxidation is
finished in the mitochondria. Both a- and b-oxidation can
occur in the peroxisomes, but mitochondria can only perform
b-oxidation. x-Oxidation occurs in the endoplasmic reticu-
lum. The focus of this article will be on mitochondrial b-
oxidation and disorders of b-oxidation, primarily acyl-CoA
dehydrogenase deficiencies.
In order for b-oxidation of fatty acids to occur, fatty acids
must first be transported into the mitochondria. Free fatty
acids are esterified with coenzyme-A to produce acyl-CoA
molecules inside the cell, which are the precursors for b-
oxidation. Long-chain fatty acids, which contain 12 or more
carbons, are believed to be actively transported into the
mitochondrial membrane. On the outer mitochondria
membrane, carnitine palmitoyltransferase-1 converts long-
chain acyl-CoA to acyl-carnitine, translocating it to in the
inner mitochondria membrane. To cross the inner mito-
chondria membrane, carnitine acyl-carnitine translocase
carries the acyl-carnitine and exchanges it for free carnitine.
Finally carnitine palmitoyltransferase-2 converts the acyl-
carnitines back to acyl-CoA. In order for FAO to occur,
transportation into the mitochondria is essential. In the case
of defects of b-oxidation, the transport system also works in
reverse, except the fatty acids remain as acyl-carnitine in the
cytosol from which they transfuse out of the cell and into
the blood (Goetzman, 2011).
Next b-oxidation occurs in the following steps: dehydro-
genation in which acyl-CoA–dehydrogenases (ACADs) cat-
alyze a double bond between C-2 and C-3 and are
noncovalently bound to flavin adenine dinucleotide (FAD) to
accept electrons; hydration of the bond between C-2 and C-3
by enoyl CoA hydratase, which is sterospecific and forms
only the l-isomer; oxidation by L-b-hydroxyacyl-CoA-
dehydrogenase, converting the hydro group to a keto group
and using NAD + as an electron acceptor; and thiolysis by b-
ketothiolase cleaving the thiol group of CoA using free CoA.
The results are an acetyl-CoA molecule and an acyl-CoA
molecule that is two carbons shorter. This process continues
shortening the acyl-CoA molecule two carbons at a time until
two molecules of acetyl-CoA are produced. Acetyl-CoA can
then go to the TCA cycle and electron transport chain and
produce 10 ATP. With the additional electrons captured
during steps 1 and 3 of b-oxidation, more ATP is made from
FAO than would be for the same carbon length glucose
chains. The electrons from the reduced FAD are removed
from the ACADs by a mechanism involving electron trans-
ferring flavoprotein, which only recently has become better
understood (Chohan et al., 2001; Leys et al., 2003; Toogood
et al., 2004).
ACADs are a family of flavoenzymes that are responsible
for catalyzing a,b-dehydrogenation of acyl-CoA and using
electron transferring flavoprotein to transfer elections. There
are at least 11 known family members that function in either
straight chain b-oxidation of fatty acids or metabolism of
branched-chain amino acids. All ACADs are processed into a
mature form in the mitochondria but are encoded in the
nuclear genome and translated in the cytoplasm. The en-
zymes involved in straight chain b-oxidation include very
long chain acyl-CoA dehydrogenase (VLCAD), acyl-CoA
dehydrogenase-9 (ACAD9), long-chain acyl-coA dehydro-
genase (LCAD), medium-chain acyl-coA dehydrogenase
(MCAD), and short-chain acyl-coA dehydrogenase (SCAD).
They are responsible for catalyzing the first steps of mito-
chondrial FAO. As their names suggest, each enzyme has
specificity for a particular chain length; for example, VLCAD
is specific for palmitoyl-CoA (C16), making it the rate-lim-
iting enzyme of long-chain fatty acid oxidation.
VLCAD gene therapy
VLCAD differs from the rest of the acyl-CoAs not only
because it is structurally active in the homodimer form, but
also because it is associated with the inner mitochondrial
membrane. VLCAD can catabolize long-chain fatty acids
from 14–24 carbons in size, and it has optimal specificity for
chain lengths 14–16 (Izai et al., 1992). The gene is approxi-
mately 5.4 kb with 20 introns located on chromosome 17
between bands p11.2 and p11.13105. The resulting protein
encoded is 67 kD in size. Prevalence of VLCAD disorder has
been reported to be from 1:30,000 to 1:85,000 (Lindner et al.,
2010).
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ACADs are responsible for catalyzing the first step in
FAO, and VLCAD is the rate-limiting ACAD. In the absence
of functional VLCAD enzyme, long-chain fatty acids are
accumulated and an energy deficiency is created. Three
phenotypes have been associated with VLCAD disorder,
representing energy deficiencies in different highly metabolic
organs. Of the three phenotypes, the earliest onset is also the
most severe. It often presents as a cardiac phenotype, with
cardiomyopathy as well as heptamegaly, hypotonia, and
hypoglycemia within the first few months of life. Another
phenotype presents during childhood, is associated with the
liver, and is characterized by reoccurring hypoketotic hy-
poglycemia. The final phenotype is the most mild, occurring
in late childhood/early adulthood with a mostly muscle
phenotype such as rhabdomyolysis and myopathy. Since the
establishment of newborn screening, patients with the two
more severe phenotypes are surviving to adulthood and are
now described as having exercise-induced rhabdomyolysis.
There has been a genotype–phenotype correlation that has
been recorded with VLCAD deficiency that is not seen with
MCAD deficiency (Andresen et al., 1999). Null mutations are
more likely to present with severe symptoms in early
childhood, and patients with missense mutations present
with milder phenotypes. However, since VLCAD does not
have a predominating mutation, and many different muta-
tions have been identified some missense mutations have
been associated with severe disease. Residual enzyme ac-
tivities of specific mutations have also been useful in pre-
dicting clinical outcomes. Patients with less than 10% activity
will develop clinical features in absence of treatment, and
patients with less than 20% may also be at risk for serious
clinical disease (Hoffmann et al., 2012). For example, one fetal
case occurred in a patient with a genotype encoding a pro-
tein that retains residual activity. This mutation is often
found in many asymptomatic patients (Coughlin and Fici-
cioglu, 2010).
VLCAD deficiency results in fatty acids being trans-
ported out of the mitochondria and accumulating in the
blood in the form of acyl-carnitines at a high frequency,
creating a metabolic block. These acyl-carnitine species are
readily detectable by tandem mass spectrometry (MS/MS).
Screening by MS/MS for specific chain length accumula-
tions provides clear evidence of a metabolic disorder; in the
case of VLCAD, C14:1, C14:2, C14, and C12:1. VLCAD
screening has been added to the standard panel as part of
the newborn screening program across all 50 states. Accu-
mulations of acyl-carnitine are measured from a dried
blood spot taken shortly after birth. Confirmation can by
made by analysis of VLCAD enzyme activity from various
tissues as well as analysis of b-oxidation of fibroblast cells.
Since the advent of newborn screening, the prevalence of
VLCAD deficiency has been revealed to be higher than
originally expected and many patients remain asymptom-
atic, suggesting they would have gone undiagnosed prior
to newborn screening.
During periods of metabolic derangement patients are
given intravenous glucose, often with insulin, and to prevent
this metabolic status, patients are to avoid fasting, myocar-
dial irritation, dehydration, high fat diets, and anesthetics
containing high doses of long-chain fatty acids. Patients
with the severe forms of VLCAD deficiency are placed on
medium-chain triglyceride (MCT) supplementation and
often have nocturnal gastric drip feedings. However, al-
though MCT supplementation is considered safe, many
question its use and long-term effects (Tucci et al. 2010, 2011).
Uncooked cornstarch is often given as a source of sustained
release glucose. Alternative experimental therapies have in-
cluded supplementation with carnitine, branched chain fatty
acids, and benzafibrate.
Early efforts at designing a gene therapy for VLCAD de-
ficiency began with modeling deficiency of LCAD, which
does not actually exist in humans, but which encompasses an
overlapping range of substrates in other mammals. Unlike
humans, mice express LCAD at high levels in metabolically
active tissues such as liver and skeletal and cardiac muscle
(Chegary et al., 2009; Maher et al., 2010). The LCAD mouse
model has a more severe phenotype then VLCAD mice,
which mimics the severe clinical phenotype of VLCAD-
deficient patients (Cox et al., 2001). Correction of LCAD +/ -
mice, which display an intermediate phenotype, was shown
by both a muscle-targeted approach (rAAV1 injected intra-
muscularly) and a liver-targeted approach (rAAV8 through
the portal vein). Reduction of the lipid peak by magnetic
resonance spectrometry (MRS) was observed in the muscle
10 weeks after IM injection or rAAV1 as well as systemic
effect on decreased macrosteatosis in the liver by Oil Red O
staining in female mice. Muscle-targeted transduction,
however, was not able to reduce acyl-carnitine accumulation
in the serum. Reduction of both macrosteatosis and micro-
steatosis was observed by Oil Red O staining after portal
vein injection of rAAV8.
Hydrodynamic injection of VLCAD into VLCAD-deficient
mice was associated with expression of functional VLCAD
protein, and in vitro correction was observed in human
VLCAD-deficient fibroblast cells by reduction of acyl-carnitine
accumulation (Merritt et al., 2006). rAAV8 gene therapy,
using the CMV promoter, by systemic tail vein injection was
published by the same group (Merritt et al., 2009). Expression
was shown in the liver of these mice at an early time point
(11 days post-injection) but was not seen at a later 102 day
post-injection time point although vector genomes were still
present. Expression of VLCAD in the heart increased be-
tween 11 and 102 days, and muscle transduction was gen-
erally poor. Correction of acyl-carnitine accumulation in the
blood as well as fasting-induced hypoglycemia were seen
throughout the study.
Most recently, a study performed using a systemic cor-
rection of VLCAD-deficient mice using rAAV9 vectors ex-
pressing VLCAD under a CMV enhancer/CB promoter. In
this study long-term expression of VLCAD protein, 147–182
days post injection, was observed in the liver and skeletal
and cardiac muscle as well as brown fat (Keeler et al., 2012).
Systemic correction was seen in reduction of blood acyl-
carnitine accumulation, but tissue-specific accumulation was
measured in the liver and heart and muscle ex vivo and in the
liver and muscle in vivo by MRS. Also for the first time
disease-specific phenotypes of cold intolerance and cold-
induced hypoglycemia and hypotonia were observed after
correction, and animals receiving AAV9-expressing VLCAD
behaved like wild-type animals (Keeler et al., 2012) (Fig. 3).
This study shows significant proof of principle for gene
therapy for VLCAD deficiency, and taken together, these
studies have important clinical applications for diseases of
mitochondrial fatty acid oxidation.
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Gene therapy for MCAD deficiency
and other FAO disorders
In 1997, Kelly et al. (1997) created a liver-specific SCAD
knock-in mouse in the SCAD-deficient mouse model. They
were able to show decreased lipid accumulation in the liver by
Oil Red O staining and systemic correction of decreased
accumulation of butyrylcarnitine in the urine. These studies
provided a foundation for gene therapy through specific
tissue targeting being possible for disorders of fatty oxidation,
and also showed that overexpression of therapeutic protein
was not detrimental. Holm et al. (2003) next showed gene
transfer to livers of SCAD-deficient mice by hydrodynamic
transfer. Although gene transfer occurred and 5% of liver cells
expressed functional SCAD proteins 31 days post injection,
systemic correction by reduced blood butyrylcarnitine after
fast was not seen. Conlon et al. (2006) published a gene ther-
apy for SCAD disorder using IM injection of rAAV1 and
rAAV2 encoding SCAD showing both correction of SCAD-
deficient patient cells in vitro and in vivo in SCAD-deficient
mice. This targeted muscle gene therapy using rAAV1
showed systemic correction of serum butyrylcarnitine levels
after fasting 10 weeks post injection. A method of detecting
lipid accumulation within specific tissues noninvasively
in vivo was also validated using MRS. Next Beattie et al. (2008)
used a liver-directed approach, like Kelly et al. (1997), but with
rAAV5 and rAAV8 for gene therapy in the SCAD-deficient
mouse. Using portal vein injections or rAAV8, protein
expression was targeted to the liver where decreases in lipid
accumulation were observed by both Oil Red O staining and
MRS 10 weeks post injection. Systemic correction was also
seen by reduction of serum butyrylcarnitines after fasting.
In vitro correction of MCAD deficiency using a rAd vector
has been performed, but so far no gene therapy in vivo has been
published for MCAD deficiency. MCAD-deficient human fi-
broblastswere infectedwith rAd vectors encodingMCAD, and
whole cell medium showed reductions of C6, C8, and C10 fatty
acids (Schowalter et al., 2005). These results are promising for
future studies of an in vivo MCAD gene therapy.
Summary
In summary, lessons learned from gene therapy clinical
trials for diseases affecting the lung such as CF and AAT
deficiency can be applied to new disease targets like disor-
ders of FAO, which were associated with SIDS prior to
newborn screening. Clinical trials have been investigated for
these disorders using a variety of vectors such as adenovirus,
AAV, and nonviral vectors. Phase 2 clinical trials for AAT
have had promising results, as well as proof of concept for
gene therapies for acyl-CoA dehydrogenase deficiencies.
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